The Impact of 3D Patch One-Suture Fixation vs No Fixation on Chronic Pain and Recurrence in Ⅲ Inguinal Hernia
Launched by NANCHONG CENTRAL HOSPITAL · Mar 11, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. primary inguinal hernia
- • 2. Type III inguinal hernia (internal annulus \>3cm)
- Exclusion Criteria:
- • 1. Age below 18 years or older than 80. recurrent hernia, incarcerated hernia,strangulated hernia, and other types of hernias.
- • 2. Patients not suitable for general anesthesia.
- • 3. Patients requiring open surgery.
- • 4. patients requiring emergency surgery Loss to follow-up or communication difficulties, or poor compliance.
About Nanchong Central Hospital
Nanchong Central Hospital is a leading healthcare institution located in Nanchong, China, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the hospital combines cutting-edge technology and a skilled team of healthcare professionals to conduct rigorous and ethical clinical research. Nanchong Central Hospital aims to contribute to the global medical community by developing new therapies and enhancing treatment protocols across various therapeutic areas, ensuring the highest standards of patient safety and scientific integrity in all its clinical endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanchong, Sichuan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported